HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Decree Sends SciLabs To Supplement Manufacturing Sideline

This article was originally published in The Tan Sheet

Executive Summary

The Irvine, Calif., firm, which makes supplements distributed under the brand All Pro Science, and CEO Paul Edalat in federal court entered a consent decree of permanent injunction with FDA and DoJ to prevent the distribution of adulterated supplements.

You may also be interested in...



More Criminal Cases Likely In Supplement, Food Safety, DoJ Official Says

The Obama administration supports pressing criminal charges in cases of contaminated or adulterated supplements or food products, and the Department of Justice is “working closely” with FDA’s food safety center, says DoJ Consumer Protection Branch official Jeffrey Steger.

Minimal Residual Disease Gains Max US FDA AdComm Support For Myeloma Trials

The US FDA’s Oncologic Drugs Advisory Committee unanimously agreed that accelerated approvals should be enabled by multiple myeloma trials using MRD as a surrogate endpoint.

Medicare Reaffirms Faith In Formulary Review Process Ahead Of Part D Changes

Dramatic transformation in the US Medicare Part D benefit design does not require any changes to CMS’ overall approach to reviewing formulary submissions from private drug plan sponsors, the agency says in its final guidance implementing the design changes for 2025.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS123913

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel